Blood:I期临床试验:依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

2019-02-08 MedSci MedSci原创

依鲁替尼单药用于既往治疗过的套细胞淋巴瘤(MCL)可获得治疗活性;但是,近一半患者在第一年会治疗失败。Peter Martin等人既往发现口服特异性的CDK4/6抑制剂palbociclib(帕博西尼)诱导的G1早期细胞周期阻滞延长,可克服人原发性MCL细胞和表达野生型BTK的MCL细胞系对依鲁替尼的耐药性。进而开展一I期临床试验评估帕博西尼联合依鲁替尼用于既往治疗过的套细胞淋巴瘤的剂量、安全性和

依鲁替尼单药用于既往治疗过的套细胞淋巴瘤(MCL)可获得治疗活性;但是,近一半患者在第一年会治疗失败。Peter Martin等人既往发现口服特异性的CDK4/6抑制剂palbociclib(帕博西尼)诱导的G1早期细胞周期阻滞延长,可克服人原发性MCL细胞和表达野生型BTK的MCL细胞系对依鲁替尼的耐药性。进而开展一I期临床试验评估帕博西尼联合依鲁替尼用于既往治疗过的套细胞淋巴瘤的剂量、安全性和治疗活性。

2014年8月-2016年6月,共招募了27位患者(21位男性、6位女性)。最大耐受剂量:依鲁替尼560mg/日+帕博西尼100mg/日,连续用药21天,28天一疗程。剂量限制性毒性是3级丘疹。最常见的3-4级毒性包括中性粒细胞减少(41%)、血小板减少(30%)、高血压(15%)、发热性中性粒细胞减少(15%)和肺炎(11%)。

中位随访25.6个月,总体和完全缓解率分别是67%和37%,2年无进展存活率为59.4%,2年缓解持续率为69.8%。现已开展II期的多中心临床试验进一步深入研究。

原始出处:

Peter Martin,et al.A phase I trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood 2019 :blood-2018-11-886457; doi: https://doi.org/10.1182/blood-2018-11-886457 

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu May 02 22:30:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 16 17:30:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Feb 20 00:30:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619534, encodeId=cea6161953487, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu May 02 22:30:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 16 17:30:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Feb 20 00:30:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619534, encodeId=cea6161953487, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu May 02 22:30:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 16 17:30:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Feb 20 00:30:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619534, encodeId=cea6161953487, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu May 02 22:30:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 16 17:30:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Feb 20 00:30:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619534, encodeId=cea6161953487, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]
    2019-02-10 nymo
  5. [GetPortalCommentsPageByObjectIdResponse(id=1702553, encodeId=d0181e025531e, content=<a href='/topic/show?id=ddc9e795159' target=_blank style='color:#2F92EE;'>#细胞淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77951, encryptionId=ddc9e795159, topicName=细胞淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=201630414353, createdName=marlenexl, createdTime=Thu May 02 22:30:00 CST 2019, time=2019-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2088721, encodeId=bfe52088e21df, content=<a href='/topic/show?id=53961018913' target=_blank style='color:#2F92EE;'>#I期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10189, encryptionId=53961018913, topicName=I期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45b2276, createdName=839640778, createdTime=Sat Mar 16 17:30:00 CST 2019, time=2019-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652858, encodeId=14531652858c8, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Wed Feb 20 00:30:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492018, encodeId=ae8114920183e, content=<a href='/topic/show?id=7d83484844c' target=_blank style='color:#2F92EE;'>#帕博西尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48484, encryptionId=7d83484844c, topicName=帕博西尼)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dde8911885, createdName=nymo, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619534, encodeId=cea6161953487, content=<a href='/topic/show?id=8dd46061824' target=_blank style='color:#2F92EE;'>#有效治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60618, encryptionId=8dd46061824, topicName=有效治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Feb 10 03:30:00 CST 2019, time=2019-02-10, status=1, ipAttribution=)]

相关资讯

Blood:脑脊液中的环形肿瘤DNA或可预测中枢神经系统淋巴瘤的预后

中心点:依鲁替尼/甲氨蝶呤/利妥昔单抗联合治疗CNS淋巴瘤安全有效脑脊液中的环形肿瘤DNA分析或可用于监测CNS淋巴瘤患者的疾病负担摘要:依鲁替尼是Bruton酪氨酸激酶(BTK)一级抑制剂,在复发性/难治性(r/r)中枢神经系统淋巴瘤(CNSL)中表现出单药活性。但临床缓解多是一过性或不完全缓解,提示需要联合用药。Christian Grommes等人开展一Ib1期临床试验,招募了15位CNSL

Blood:采用依鲁替尼治疗慢性淋巴细胞白血病,一个疗程后可适当降低剂量

依鲁替尼疗效高,治疗慢性淋巴细胞白血病(CLL)时标准剂量420mg/d。研究人员既往发现依鲁替尼治疗一疗程后,CLL细胞中的BTK蛋白水平降低,提示可在第一个疗程后降低依鲁替尼剂量,且不影响生物学效应。为验证该假设,研究人员设计了一个预实验系统的降低同一批患者在3个28天疗程内的依鲁替尼剂量。第一个疗程420mg/d、第二个疗程剂量降至280mg/d、第3个疗程降至140mg/d。共有11位患者

Blood:体外激活和依鲁替尼治疗可恢复CLL Vγ9Vδ2-T细胞的抗CLL细胞的细胞毒性作用

中心点:健康的Vγ9Vδ2-T细胞可识别裂解CLL细胞,但CLL患者来源的Vγ9Vδ2-T细胞的细胞毒性和细胞因子合成受损。用自体moDCs在体外激活Vγ9Vδ2-T细胞可逆转其功能障碍,依鲁替尼可促进产生抗肿瘤的TH1表型。摘要:自体(αβ)T细胞为基础的治疗策略用于慢性淋巴细胞白血病(CLL)的疗效一直较为温和。具有强力的抗淋巴瘤活性的细胞毒性T淋巴细胞通过主要组织相容性复合物(MHC)非依赖

Blood:依鲁替尼可有效治疗Bing-Neel综合征!

Bing-Neel综合征(宾一尼综合征),又称为神经精神病巨球蛋白血症综合征,是一种罕见疾病,特点是巨球蛋白血症合并中枢神经系统症状,主要发生于50岁以上的中老年人。中心点:依鲁替尼被用于治疗28位Bing-Neel综合征(BNS)患者。依鲁替尼在BNS患者中表现出快速、持久的症状和影像学缓解。摘要:BNS尚无标准疗法。Jorge J. Castillo等人招募巨球蛋白血症(WM)和影像学和(或)

Lancet oncol:依鲁替尼联合奥比托珠单抗治疗慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的效果和安全性

单用依鲁替尼和苯丁酸氮芥联合奥比托珠单抗的效果均优于苯丁酸氮芥单药治疗,是慢性淋巴细胞白血病的标准一线疗法。现研究人员开展研究对比依鲁替尼联合奥比托珠单抗和苯丁酸氮芥联合奥比托珠单抗作为慢性淋巴细胞白血病或小淋巴细胞淋巴瘤的一线疗法的治疗效果。iLLUMINATE是在澳大利亚、加拿大等多个国家的74家医院进行的随机开放的3期试验,招募既往未治疗过的年满65岁的慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患

Blood:依鲁替尼联合利妥昔单抗与依鲁替尼单药治疗慢性淋巴细胞白血病的效果对比

中心点:依鲁替尼加利妥昔单抗治疗复发性和未治疗过的高风险的CLL患者,并未提高PFS.依鲁替尼联合利妥昔单抗治疗的患者更快地获得缓解,显着减少残余病灶。摘要:依鲁替尼,一种口服的Bruton酪氨酸激酶(BTK)共价抑制剂,可有效治疗CLL。利妥昔单抗能否在依鲁替尼的基础上锦上添花?Jan A. Burger等人对此展开研究。研究人员招募了208位CLL患者(181位复发性CLL患者,27位未治疗过